Merck's full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...

Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...

The drugmaker’s guidance was affected by a pause in shipments of its top-selling vaccine to China from February through at ...

(Reuters) - Merck said it will pause shipments of Gardasil to China through at least mid-year, as continued weak demand for ...

Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the ...

The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is ...

Merck reported a 2% decline in Gardasil sales, after reaching a peak of $8.9 billion in 2023. Now with shipments to China paused, the HPV vaccine faces significant headwinds going into 2025.

Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of its HPV vaccine, Gardasil, to reach $11 billion by 2030. The result: a 10% ...

Mr. Kennedy has referred clients to the firm in cases claiming injuries from the Gardasil vaccine, a Merck product that is meant to prevent cervical cancer that can be caused by the human ...

Wisner Baum is representing a plaintiff in a trial against Merck and other lawsuits are ... in Wisner Baum's suits against Merck over its HPV vaccine, which is to prevent cervical cancer.

However, Merck faced a setback when Barclays (LON:BARC) Capital Inc. lowered its price target to $142, citing a reset in revenue estimates for the company's China Gardasil business. The adjustment ...

However, Merck faced a setback when Barclays (LON:BARC) Capital Inc. lowered its price target to $142, citing a reset in revenue estimates for the company's China Gardasil business. The adjustment ...